Monday 13th February 2023   We are pleased to invite investors and analysts to participate in our virtual event on Monday, 13 February 2023, highlighting Roche data presented at the virtual Angiogenesis, Exudation, and Degeneration 2023 Meeting, from 10th to 11th February.   16:30 – 18:00 CET / 15:30 – 17:00 GMT 10:30 – 12:00 pm EST / 7:30 – 9:00 am PST   Agenda Welcome - Bruno Eschli, Head of Investor Relations Roche ophthalmology strategy - Nilesh Mehta, Global Franchise Head of Ophthalmology Roche ophthalmology pipeline - Christopher Brittain, Vice President and Global Head of Ophthalmology Product Development Key data presented at Angiogenesis - Veeral S. Sheth, MD, MBA, FASRS, FACS, Retina Specialist and Clinical Investigator   The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:30 CET on the day of the event. > click here Access to virtual event (pre-registration required) Please pre-register for our webinar here*.   Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.   A replay of the webcast will be available via > ir.roche.com   *privacy notice     Best regards,
Bruno Eschli Head of Investor Relations		Loren Kalm Head of Investor Relations, North America

Roche Investor Relations
Dr. Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.com	Dr. Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com	Dr. Gerard Tobin Phone: +41 61 68-72942 e-mail: gerard.tobin@roche.com
Investor Relations North America
Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com

 

get the latest news and updates to your inbox.